171 related articles for article (PubMed ID: 17106834)
1. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
Maiuri F; Del Basso De Caro ML; Iaconetta G; Peca C; Esposito M; de Divitiis E
Zentralbl Neurochir; 2006 Nov; 67(4):204-9. PubMed ID: 17106834
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
Majumdar K; Radotra BD; Vasishta RK; Pathak A
Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
4. Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.
Tena-Suck ML; Moreno-Jiménez S; Alonso M; Aguirre-Crux L; Sánchez A
Ann Diagn Pathol; 2008 Oct; 12(5):313-21. PubMed ID: 18774492
[TBL] [Abstract][Full Text] [Related]
5. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors.
Hu TH; Lin JW; Chen HH; Liu LF; Chuah SK; Tai MH
Dis Colon Rectum; 2009 Feb; 52(2):319-26. PubMed ID: 19279430
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
Kros JM; Hop WC; Godschalk JJ; Krishnadath KK
Cancer; 1996 Sep; 78(5):1107-13. PubMed ID: 8780550
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 in oligodendroglial neoplasms.
Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
Hagel C; Krog B; Laas R; Stavrou DK
J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results of treatment in patients with oligodendrogliomas and oligoastrocytomas of the cerebral hemispheres].
Iun'pén V; Oliushin VE; Ulitin AIu; Maslova LN; Petrov AA
Zh Vopr Neirokhir Im N N Burdenko; 2008; (2):6-10; discussion 10-1. PubMed ID: 18720725
[TBL] [Abstract][Full Text] [Related]
10. Oligodendroglioma: does deferring treatment compromise outcome?
Feigenberg SJ; Amdur RJ; Morris CG; Mendenhall WM; Marcus RB; Friedman WA
Am J Clin Oncol; 2003 Jun; 26(3):e60-6. PubMed ID: 12796617
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic significance of proliferating cell nuclear antigen and Ki-67 in malignant ovarian germ cell tumors.
Liu FS; Chen JT; Liu SC; Shih A; Shih RT; Ho ES
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):695-702. PubMed ID: 10533299
[TBL] [Abstract][Full Text] [Related]
12. Oligodendrogliomas in the CT/MR-era.
Leonardi MA; Lumenta CB
Acta Neurochir (Wien); 2001 Dec; 143(12):1195-203. PubMed ID: 11810382
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
Mauer ME; Taphoorn MJ; Bottomley A; Coens C; Efficace F; Sanson M; Brandes AA; van der Rijt CC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ;
J Clin Oncol; 2007 Dec; 25(36):5731-7. PubMed ID: 18089867
[TBL] [Abstract][Full Text] [Related]
14. [Results in oligodendroglioma: postoperative radiotherapy combined with chemotherapy].
Kitahara M; Katakura R; Mashiyama S; Niizuma H; Yoshimoto T; Suzuki J; Mori T; Wada T
No Shinkei Geka; 1987 Apr; 15(4):397-403. PubMed ID: 3614532
[TBL] [Abstract][Full Text] [Related]
15. Correlation of proliferative markers (Ki-67 and PCNA) with survival and lymph node metastasis in oral squamous cell carcinoma: a clinical and histopathological analysis of 113 patients.
Myoung H; Kim MJ; Lee JH; Ok YJ; Paeng JY; Yun PY
Int J Oral Maxillofac Surg; 2006 Nov; 35(11):1005-10. PubMed ID: 17018251
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Oligodendroglioma: CD44 as a possible prognostic opportunity.
Buccoliero AM; Caldarella A; Arganini L; Mennonna P; Ammanati F; Taddei A; Taddei GL
Clin Neuropathol; 2003; 22(4):169-75. PubMed ID: 12908752
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma.
Reis-Filho JS; Faoro LN; Carrilho C; Bleggi-Torres LF; Schmitt FC
Cancer; 2000 Feb; 88(4):862-9. PubMed ID: 10679656
[TBL] [Abstract][Full Text] [Related]
19. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
20. Proliferating cell nuclear antigen as a prognostic factor after total mesorectal excision of stage II-III rectal cancer.
Huh JW; Kim HR; Kim YJ
Ann Surg Oncol; 2009 Jun; 16(6):1494-500. PubMed ID: 19267156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
